ClinicalTrials.gg
RecruitingNCT04933188Updated Mar 18, 2024

Early Detection of Myocardial Work Impairment in Obesity II(EARLY-MYO-OBESITY-II)

An observational study in Overweight and Obesity, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by RenJi Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started May 2019; still recruiting 7 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Obesity by RenJi Hospital — 6 open to participants now, 6 under way, none of them phase 3. Obesity · RenJi Hospital.

Started
2019
with 1 other
Observational
3 of 10
2 open now
Registered
2nd of 10
by date

Among the 10 studies in Obesity by RenJi Hospital, this one is one of 2 that started in 2019, is one of 3 observational ones, and was the 2nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

6 of the 10 studies in Obesity by RenJi Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity by RenJi Hospital, or all of them as a file.
02

Study summary

This prospective study intends to explore the change of cardiac structure and function in the cohort of overweight or obesity patients, and determine the impact of clinical characteristics on cardiac remodeling and mechanics.

Read the detailed description

Obesity significantly increases the risk for heart failure. Early detection of preclinical cardiac dysfunction in overweight or obesity and understanding its association with insulin resistance are of great importance.Recently, a novel technique for myocardial work (MW) assessment has been introduced to evaluate myocardial performance. To date, change of MW has been described in several cardiac conditions including dilated cardiomyopathy, significant coronary arterial diseases, and hypertrophic cardiomyopathy, which implies regional or global myocardial dysfunction. In this study, we aimed to explore the alteration of MW in overweight or obese adults and to determine whether insulin resistance or other clinical risk factors may impact myocardial mechanics before impairment of systolic function.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 200 is above the median of 115 across 2,159 observational studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

overweight or obese subjects referred to the endocrinology inpatients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients were older than 18 without any cardiac symptoms.
  • The diagnosis of overweight was established when (BMI) of 25 to 30 kg/m2.
  • Obese was defined as a BMI of 30 kg/m2 or higher.

Exclusion criteria

Exclusion Criteria:

  • diagnosis of type 2-Diabetes Mellitus according to the American Diabetes Association criteria;
  • \<50% on echocardiography;
  • arrythmia on ;
  • severe valvular stenosis or regurgitation;
  • history of coronary disease (defined as stenosis>50%) or myocardial infarction;
  • stress induced wall motion abnormality on echocardiography, coronary artery stenosis >50% on coronary CT or angiography with Framingham risk score of >10;
  • pacemaker or defibrillator implantation;
  • the presence of bundle branch block;
  • severe infection or renal dysfunction with an estimated \< 60 ml/min/1.73 m2);
  • inadequate image quality on echocardiography.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • control

    Lean health controls with a BMI\<25kg/m2

    Diagnostic Test: Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure

  • overweight

    patients with a BMI of 25-30kg/m2

    Diagnostic Test: Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure

  • obesity

    patients with a BMI of over 30kg/m2

    Diagnostic Test: Myocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure

Interventions

  • Diagnostic testMyocardial work was estimated from left ventricular pressure-strain loop derived from speckle tracking echocardiography and non-invasive brachial artery cuff pressure

    Baseline and follow-up examination of echocardiography is to be performed on study subjects.

07

What researchers measure

Primary outcomes

  1. investigate the change of global myocardial work index (GWI) in overweight or obese patients

    GWI derived from echocardiography will be assessed in overweight or obese patients and compare with lean controls

    Time frame: within 24 hours of the recruitment

  2. investigate the change of global constructive work (GCW) in overweight or obese patients

    GCW will be assessed in overweight or obese patients and compare with lean controls

    Time frame: within 24 hours of the recruitment

  3. investigate the change of global waste work (GWW) in overweight or obese patients

    GWW will be assessed in overweight or obese patients and compare with lean controls

    Time frame: within 24 hours of the recruitment

  4. investigate the change of global work efficiency (GWE) in overweight or obese patients

    GWE will be assessed in overweight or obese patients and compare with lean controls

    Time frame: within 24 hours of the recruitment

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2019 (actual). Primary completion is estimated for Dec 2024, 67 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 67 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2021
First posted
Jun 21, 2021
StartActual
May 1, 2019
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04933188
Lead sponsor
RenJi Hospital
Collaborators
Ningbo Hangzhou Bay Hospital, Jiading Central Hospital
Responsible party
Sponsor
First posted
Jun 21, 2021
Start date
May 1, 2019
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 18, 2024

Study contacts

Hang Zhao
Contact
zara_hang@163.com
+8613764477850
Meng Jiang
study director · Renji Hospital, Shanghai

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion